Craig-Hallum raised the firm’s price target on GeneDx (WGS) to $95 from $70 and keeps a Buy rating on the shares. The firm remains positive following a significant Q3 beat and raise and achievement of adjusted Net Income profitability several quarters sooner than it had expected.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS: